RU2020135055A - Тройная фармацевтическая комбинация, включающая дабрафениб, траметиниб и ингибитор erk - Google Patents
Тройная фармацевтическая комбинация, включающая дабрафениб, траметиниб и ингибитор erk Download PDFInfo
- Publication number
- RU2020135055A RU2020135055A RU2020135055A RU2020135055A RU2020135055A RU 2020135055 A RU2020135055 A RU 2020135055A RU 2020135055 A RU2020135055 A RU 2020135055A RU 2020135055 A RU2020135055 A RU 2020135055A RU 2020135055 A RU2020135055 A RU 2020135055A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- pharmaceutical combination
- per day
- fluorophenyl
- fluoro
- Prior art date
Links
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 title claims 9
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 title claims 9
- 229960002465 dabrafenib Drugs 0.000 title claims 5
- 229960004066 trametinib Drugs 0.000 title claims 5
- 239000012824 ERK inhibitor Substances 0.000 title 1
- 206010009944 Colon cancer Diseases 0.000 claims 13
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 claims 4
- 229940126062 Compound A Drugs 0.000 claims 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims 3
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 102200055464 rs113488022 Human genes 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229960001308 trametinib dimethyl sulfoxide Drugs 0.000 claims 1
- OQUFJVRYDFIQBW-UHFFFAOYSA-N trametinib dimethyl sulfoxide Chemical compound CS(C)=O.CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 OQUFJVRYDFIQBW-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650744P | 2018-03-30 | 2018-03-30 | |
| US62/650,744 | 2018-03-30 | ||
| PCT/IB2019/052601 WO2019186488A1 (en) | 2018-03-30 | 2019-03-29 | A triple pharmaceutical combination comprising dabrafenib, trametinib and an erk inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020135055A true RU2020135055A (ru) | 2022-05-05 |
| RU2020135055A3 RU2020135055A3 (enExample) | 2022-09-22 |
Family
ID=66397350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020135055A RU2020135055A (ru) | 2018-03-30 | 2019-03-29 | Тройная фармацевтическая комбинация, включающая дабрафениб, траметиниб и ингибитор erk |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210121460A1 (enExample) |
| EP (1) | EP3773586A1 (enExample) |
| JP (1) | JP2021519285A (enExample) |
| KR (1) | KR20200138303A (enExample) |
| CN (1) | CN111936141A (enExample) |
| AU (1) | AU2019246719B2 (enExample) |
| BR (1) | BR112020019577A2 (enExample) |
| CA (1) | CA3094780A1 (enExample) |
| CL (1) | CL2020002505A1 (enExample) |
| IL (1) | IL277380A (enExample) |
| MX (1) | MX2020010231A (enExample) |
| RU (1) | RU2020135055A (enExample) |
| WO (1) | WO2019186488A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230090389A1 (en) * | 2020-02-28 | 2023-03-23 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor |
| IL295626A (en) * | 2020-02-28 | 2022-10-01 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor |
| KR20240055721A (ko) * | 2021-06-24 | 2024-04-29 | 아사나 바이오사이언시스 엘엘씨 | Erk1/2 억제제 조합 요법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100883289B1 (ko) | 2004-06-11 | 2009-02-11 | 니뽄 다바코 산교 가부시키가이샤 | 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물 |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| DK3063143T3 (en) * | 2013-11-01 | 2018-08-20 | Novartis Ag | Amino heteroaryl benzamides as kinase inhibitors |
| CA2991805A1 (en) * | 2015-07-10 | 2017-01-19 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
| CN109715163B (zh) * | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | 包含raf抑制剂和erk抑制剂的治疗组合 |
-
2019
- 2019-03-29 AU AU2019246719A patent/AU2019246719B2/en not_active Ceased
- 2019-03-29 MX MX2020010231A patent/MX2020010231A/es unknown
- 2019-03-29 CA CA3094780A patent/CA3094780A1/en active Pending
- 2019-03-29 WO PCT/IB2019/052601 patent/WO2019186488A1/en not_active Ceased
- 2019-03-29 BR BR112020019577-4A patent/BR112020019577A2/pt not_active Application Discontinuation
- 2019-03-29 CN CN201980021573.3A patent/CN111936141A/zh active Pending
- 2019-03-29 KR KR1020207030757A patent/KR20200138303A/ko not_active Withdrawn
- 2019-03-29 JP JP2020551481A patent/JP2021519285A/ja active Pending
- 2019-03-29 RU RU2020135055A patent/RU2020135055A/ru unknown
- 2019-03-29 EP EP19721810.0A patent/EP3773586A1/en not_active Withdrawn
- 2019-03-29 US US17/042,591 patent/US20210121460A1/en not_active Abandoned
-
2020
- 2020-09-15 IL IL277380A patent/IL277380A/en unknown
- 2020-09-28 CL CL2020002505A patent/CL2020002505A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3094780A1 (en) | 2019-10-03 |
| CN111936141A (zh) | 2020-11-13 |
| BR112020019577A2 (pt) | 2021-01-05 |
| IL277380A (en) | 2020-11-30 |
| KR20200138303A (ko) | 2020-12-09 |
| CL2020002505A1 (es) | 2021-03-05 |
| JP2021519285A (ja) | 2021-08-10 |
| EP3773586A1 (en) | 2021-02-17 |
| AU2019246719A1 (en) | 2020-10-01 |
| US20210121460A1 (en) | 2021-04-29 |
| AU2019246719B2 (en) | 2022-06-16 |
| MX2020010231A (es) | 2020-10-28 |
| WO2019186488A1 (en) | 2019-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532051A5 (enExample) | ||
| CN112867512A (zh) | 联合疗法 | |
| RU2006109467A (ru) | Способы лечения рака с использованием ингибиторов hdac | |
| RU2006136881A (ru) | Фармацевтическая композиция, содержащая производное бензодиазепина и ингибитор белка слияния rsv | |
| FI4013412T3 (fi) | Ripretinibi ruoansulatuskanavan stroomakasvaimien hoitoon | |
| JP2009512719A5 (enExample) | ||
| NZ582089A (en) | Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir | |
| JP2005538099A5 (enExample) | ||
| RU2017102319A (ru) | Прерывистое введение ингибитора mdm2 | |
| JP2018512403A5 (enExample) | ||
| JP2015522033A5 (enExample) | ||
| CN120860270A (zh) | 稳定的、浓缩的放射性核素络合物溶液 | |
| KR20170007868A (ko) | Ｂｃｒ-ａｂｌ, ｃ-ｋｉｔ, ｄｄｒ1, ｄｄｒ2 또는 ｐｄｇｆ-ｒ 키나제 활성에 의해 매개된 증식성 장애 및 다른 병적 상태의 치료 방법 | |
| US20210040050A1 (en) | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof | |
| RU2012147511A (ru) | Применение ингибиторов c-src в комбинации с пиримидиламинобензамидом для лечения лейкоза | |
| CN1511036B (zh) | 包含信号转导抑制剂和埃坡霉素衍生物的联合形式 | |
| JP2022107687A (ja) | ペメトレキセドまたはその薬剤学的に許容可能な塩を含有する安定化された薬学組成物 | |
| JP2021519285A5 (enExample) | ||
| JP2021503457A5 (enExample) | ||
| WO2015134561A1 (en) | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection | |
| US10695296B2 (en) | Formulations, methods, kit, and dosage forms for improved stability of an active pharmaceutical ingredient | |
| JP2016502540A5 (enExample) | ||
| JP2014512362A5 (enExample) | ||
| TW201625637A (zh) | 經胺醇取代之２，３－二氫咪唑［１，２－ｃ］喹唑啉衍生物之給藥方案 | |
| EA200600377A1 (ru) | Новая композиция |